77P - Adjuvant chemotherapy in resected stage Ib-III non small cell lung cancer

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Early Stage
Non-Small-Cell Lung Cancer, Locally Advanced
Presenter Betty Zhang
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors B. Zhang1, H. Wong1, D. Gunawardana2, P. Parente1, R. de Boer2, A. Barling3, P. Antippa4, R. Wong1
  • 1Medical Oncology, Eastern Health, 3128 - Box Hill/AU
  • 2Medical Oncology, Royal Melbourne Hospital, Parkville/AU
  • 3Cardiothoracic Surgery, Eastern Health, Box Hill/AU
  • 4Cardiothoracic Surgery, Royal Melbourne Hospital, Parkville/AU


A substantial proportion of patients (pts) with resected stage I, II or III non small cell lung cancer (NSCLC) recur and die. Adjuvant chemotherapy (CT) using platinum-based regimens is recommended for pts with stage II and III NSCLC, and may have a role in stage IB disease. The aim was to evaluate the role of adjuvant CT following complete resection of NSCLC in a real life setting.